PIPc study: development of indicators of potentially inappropriate prescribing in children (PIPc) in primary care using a modified Delphi technique by Barry, Emma et al.
PIPc study: development of indicators of potentially
inappropriate prescribing in children (PIPc) in primary care using
a modified Delphi technique
Barry, E., O'Brien, K., Moriarty, F., Cooper, J., Redmond, P., Hughes, C. M., ... Smith, S. M. (2016). PIPc study:
development of indicators of potentially inappropriate prescribing in children (PIPc) in primary care using a
modified Delphi technique. BMJ Open, 6(9), [e012079 ]. DOI: 10.1136/bmjopen-2016-012079
Published in:
BMJ Open
Document Version:
Publisher's PDF, also known as Version of record
Queen's University Belfast - Research Portal:
Link to publication record in Queen's University Belfast Research Portal
Publisher rights
Copyright 2016 Barry E, et al. BMJ Open
This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license,
which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms,
provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
General rights
Copyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and / or other
copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated
with these rights.
Take down policy
The Research Portal is Queen's institutional repository that provides access to Queen's research output. Every effort has been made to
ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the
Research Portal that you believe breaches copyright or violates any law, please contact openaccess@qub.ac.uk.
Download date:15. Feb. 2017
PIPc study: development of indicators
of potentially inappropriate prescribing
in children (PIPc) in primary care using
a modiﬁed Delphi technique
Emma Barry,1 Kirsty O’Brien,1 Frank Moriarty,1 Janine Cooper,2 Patrick Redmond,1
Carmel M Hughes,2 Kathleen Bennett,1 Tom Fahey,1 Susan M Smith,1
The PIPc Project Steering group
To cite: Barry E, O’Brien K,
Moriarty F, et al. PIPc study:
development of indicators of
potentially inappropriate
prescribing in children (PIPc)
in primary care using a
modified Delphi technique.
BMJ Open 2016;6:e012079.
doi:10.1136/bmjopen-2016-
012079
▸ Prepublication history and
additional material is
available. To view please visit
the journal (http://dx.doi.org/
10.1136/bmjopen-2016-
012079).
Received 28 March 2016
Revised 31 May 2016
Accepted 1 July 2016
1Department of General
Practice, HRB Centre for
Primary Care Research, Royal
College of Surgeons in
Ireland, Dublin, Ireland
2Clinical and Practice
Research Group, School of
Pharmacy, Queen’s University
Belfast, Belfast, UK
Correspondence to
Professor Susan M Smith;
susansmith@rcsi.ie
ABSTRACT
Objective: There is limited evidence regarding the
quality of prescribing for children in primary care.
Several prescribing criteria (indicators) have been
developed to assess the appropriateness of prescribing
in older and middle-aged adults but few are relevant to
children. The objective of this study was to develop a
set of prescribing indicators that can be applied to
prescribing or dispensing data sets to determine the
prevalence of potentially inappropriate prescribing in
children (PIPc) in primary care settings.
Design: Two-round modified Delphi consensus
method.
Setting: Irish and UK general practice.
Participants: A project steering group consisting of
academic and clinical general practitioners (GPs) and
pharmacists was formed to develop a list of indicators
from literature review and clinical expertise. 15 experts
consisting of GPs, pharmacists and paediatricians from
the Republic of Ireland and the UK formed the Delphi
panel.
Results: 47 indicators were reviewed by the project
steering group and 16 were presented to the Delphi
panel. In the first round of this exercise, consensus
was achieved on nine of these indicators. Of the
remaining seven indicators, two were removed
following review of expert panel comments and
discussion of the project steering group. The second
round of the Delphi process focused on the remaining
five indicators, which were amended based on first
round feedback. Three indicators were accepted
following the second round of the Delphi process and
the remaining two indicators were removed. The final
list consisted of 12 indicators categorised by
respiratory system (n=6), gastrointestinal system (n=2),
neurological system (n=2) and dermatological system
(n=2).
Conclusions: The PIPc indicators are a set of
prescribing criteria developed for use in children in
primary care in the absence of clinical information. The
utility of these criteria will be tested in further studies
using prescribing databases.
BACKGROUND
Quality of prescribing for children has been
identiﬁed as an area of concern since the
late 1970′s, when it was reported that 60% of
children under 14 years received at least one
prescription a year from their family practi-
tioner.1 Currently, children represent over
25% of the population and receive an
average of three prescription medications
before 5 years of age.2 There are ongoing
concerns over the quality of prescribing for
children, but there is a lack of studies in this
area.3 Potential consequences for children
may be adverse drug events leading to
unplanned hospital admissions and prevent-
able deaths.4
Medicines are generally considered appro-
priate in an adult population when they have
a clear evidence-based indication, are well
tolerated in the majority of patients and are
cost effective.5 Medicines or prescribing pat-
terns that do not ﬁt this description can be
considered inappropriate; this term includes
Strengths and limitations of this study
▪ The members of Delphi panel in this study were
heterogeneous in experience and setting, and
represented the professions involved in prescrib-
ing and dispensing to children.
▪ The Delphi process used in the study followed
predefined methodology in line with best
practice.
▪ Dispensing databases may not contain clinical
information, limiting the application of indicators
that require such information for interpretation.
▪ The reliability of the Delphi technique as a
method for achieving consensus has been
debated but its potential limitations are similar to
other consensus techniques.
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misprescribing, underprescribing and overprescribing.6
Misprescribing includes the incorrect prescription of an
indicated medication and can be divided into drug
choice, dosage, duration of therapy, duplication of drugs
of the pharmacological class and drug–disease or drug–
drug interactions or drug–food interactions.
Underprescribing includes the omission of a prescrip-
tion that is needed and overprescribing; the prescription
of a medication that is unnecessary.7 The term ‘poten-
tially inappropriate prescribing’ acknowledges the reality
of prescribing in clinical practice, whereby the prescrip-
tion of an inappropriate medication may be justiﬁed by
the individual needs of a particular patient.8 For
example, sedating antihistamines may be considered
inappropriate for young children because of the risk of
side effects such as sedation, paradoxical excitation and
potential cardiac toxicity. However, they may, in some
instances, be useful in the treatment of insomnia relat-
ing to itch caused by eczema.
Research into potentially inappropriate prescribing in
adults has focused on the development of indicators or
explicit criteria of prescribing, which are measurable cri-
teria against which quality standards can be set and
audited. Explicit indicators, such as the Screening Tool
to Alert doctors to the Right Treatment/Screening Tool
of Older Peoples’ potentially inappropriate Prescriptions
(START/STOPP) criteria, were devised to identify PIP
in older adults and have been found to be valid, reliable
and generalisable across international primary care
settings.9
To date, many quality indicators of care of children in
primary care relate to speciﬁc diseases or conditions
such as mental health or diabetes.10 11 More recent
work in France has led to the development of the ﬁrst
set of indicators of inappropriate prescribing in children
for use in hospital and community settings.12
Researchers in the UK have also developed primary care
quality indicators for children that include some pre-
scribing indicators but focus on broader issues such as
the management and assessment of clinical conditions,
child development and child protection.13 Other criteria
have been developed for use in the out-of-hours setting
and in paediatric emergency departments.14 15
Recent studies have highlighted that explicit prescrib-
ing indicators are not sufﬁcient to assess whether pre-
scribing is appropriate or not in the context of assessing
daily prescribing practices.16 Ideally, a prescribing indica-
tor would be based on a thorough review of patient
records with access to the full clinical and treatment
history of the patient. Nonetheless, this process is time
consuming and can be extremely complex.17 18
Although the evidence base for developing explicit pre-
scribing indicators is limited, combining expert profes-
sional opinion with consensus methodology can create
quality indicators in areas where it would not otherwise
be possible.19 Explicit indicators can be useful in asses-
sing the quality of prescribing using large national pre-
scribing databases without clinical information.20
This study aims to create indicators that are based on
commonly prescribed medications to children in
primary care and are supported by international best
practice guidelines.
METHOD
Study design
A modiﬁed Delphi consensus technique was used to
develop these prescribing criteria. This technique allows
an estimate of an overall group opinion to be reached
by improving agreement between a panel of experts
through rounds of questionnaires.21 The Delphi panel
was modiﬁed as direct feedback would not be provided
to the Delphi panel members between rounds. Ethical
approval for this study was obtained from the Royal
College of Surgeons in Ireland (RCSI) Research Ethics
Committee, Dublin, Ireland in April 2014.
Compilation of initial indicators
We undertook a comprehensive literature search using
PubMed to identify any previously developed indicators
relating to potentially inappropriate prescribing in chil-
dren (PIPc). Online supplementary ﬁle 1 shows the
search string used. As very few indicators from lists
devised for adults or older adults are applicable to chil-
dren, the search strategy was limited to include only
those articles involving infants, children or adolescents.
The search was performed initially in April 2014 and
updated in August 2015.
A set of initial indicators were identiﬁed from the litera-
ture search. Clinical guidelines, web sources and PubMed
were used to identify the best available evidence to support
each indicator. Online supplementary ﬁle 2 details a full
list of information sources used. The British National
Formulary for Children (BNFc)22 and the Irish Medicines
Formulary (IMF)23 were used as reference resources for
indication, dosages and licensing information.
A project steering group was formed to guide the
development of the indicators using predeﬁned inclu-
sion and exclusion criteria. The steering group consisted
of academic/clinical general practitioners (GPs), three
academic/clinical pharmacists, a pharmacoepidemiolo-
gist/statistician and a postdoctoral researcher, all
members of either the HRB Centre for Primary Care
Research at the RCSI Dublin or the School of Pharmacy
at Queen’s University Belfast.
Inclusion criteria are as follows: indicators had to:
▸ describe a pattern of prescribing that was potentially
hazardous or known to be ineffective
▸ describe a pattern of prescribing that was not in
keeping with best practice or current guidelines
▸ apply to the population of interest; children <16 years
Exclusion criteria are as follows:
▸ medications currently unavailable in the study setting
▸ criteria which could not be applied in the absence of
clinical information
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▸ criteria containing medications with a low prevalence
of use (to deﬁne uncommon use, a cut-off of <0.5/
1000 General Medical Scheme (GMS) patients was
agreed by the project steering group)
Members of the project steering group applied the
inclusion and exclusion criteria and examined the evi-
dence supporting each indicator. For example, the criter-
ion ‘Fluoxetine is the most appropriate antidepressant
for children, other SSRIs should not be prescribed’ was
removed by the project steering group during this screen-
ing stage as the criterion related speciﬁcally to patients
with depression and could not be successfully applied in
the absence of clinical information. Some criteria identi-
ﬁed from literature were modiﬁed by the project steering
group to make them applicable to dispensing database
without clinical information, for example, ‘Children with
eczema should be prescribed an emollient’ was altered to
‘An emollient should be prescribed to children who are
prescribed greater than one topical corticosteroid in a
year’, where the prescription of greater than one topical
corticosteroid in a year was considered a proxy for a diag-
nosis of eczema. Supplementary ﬁle 3 details the indica-
tors removed and the reasons for exclusion by the project
steering group.
The primary care reimbursement service database (PCRS)
The prevalence of individual drug use in children in
2011 was determined using dispensing data from the
Health Service Executive-Primary Care Reimbursement
Service (HSE-PCRS). The PCRS is a national dispensing
database in Ireland; it stores information on all medica-
tions and other health services, provided without charge
to people eligible for free medical services in Ireland
under the GMS. Eligibility for free medical care is estab-
lished via means testing and therefore the data collected
by the PCRS is not fully representative of the entire
population of Ireland. Approximately 39% (414 856) of
the total population (1 072 220) of children <16 years in
the Republic of Ireland were eligible for the scheme in
2014. The PCRS contains data on prescriptions originat-
ing in primary and secondary care for all children who
are eligible for free medical services. Children who
receive a prescription from a hospital specialist will have
their prescription transcribed to a GMS prescription by
their GP in order to avail of free medication. The PCRS
does not record data on whether a prescription has ori-
ginated in primary or secondary care. An Anatomical
Therapeutic Chemical Classiﬁcation System (ATC) code
was assigned to each indicator to allow for extraction
from the dispensing database.
Selection of the Delphi panel
In total, 30 specialists from the UK and Republic of
Ireland were invited a priori (via email) to participate in
a Delphi panel to develop these criteria. Although no
speciﬁc standard was applied to deﬁne an expert, the
specialists invited to participate on the panel were peer
recognised as experts in their ﬁelds by the project
steering group and consisted of academic and clinical
GPs, paediatricians and pharmacists. A total of 18 specia-
lists agreed to participate. The panel consisted of nine
experts from the Republic of Ireland (three GPs, three
paediatricians, three pharmacists) and nine from the
UK (three GPs three paediatricians, three pharmacists).
Written consent was received before starting the process.
Data collection and analysis
The consensus process involved two rounds of web-based
questionnaires. The questionnaire was piloted among
the project steering group and GP members of the
Department of General Practice, RCSI with minor modi-
ﬁcations made subsequently. The ﬁrst and second
rounds of the questionnaires were sent to the Delphi
panel between January 2015 and May 2015 and between
June 2015 and July 2015, respectively. For each round,
panel members were emailed a link to a questionnaire
which was maintained on an online survey software tool
(SurveyGizmo). Panellists were presented with each indi-
cator and an accompanying rationale for the indicator,
categorised by physiological systems (gastrointestinal
system, respiratory system, central nervous system, der-
matological system) along with a hyperlink to a support-
ing evidence resource, for example, Cochrane systematic
review, the BNFc or national or international guidelines.
Panellists were asked to indicate their level of agreement
with each indicator using a ﬁve-point Likert scale,24
(where 1 was strongly disagree and 5 was strongly agree)
and to provide comments within a free text box.
Following completion of the ﬁrst round of question-
naires, the median response and the IQR for each indi-
cator were calculated from the Likert scale. The level
required for consensus between the panel members was
decided prior to starting the study. When the upper
quartile was ≤2, this indicated there was consensus by
the Delphi panel members on rejection of the indicator.
When the lower quartile was ≥4, this indicated there was
consensus by the Delphi panel members on acceptance
of the indicator. When the IQR included 3, this indi-
cated there was a lack of agreement between the panel
members and a need for further review of the particular
indicator. These indicators were reviewed by project
steering group and were either revised and included in
the second questionnaire or rejected based on the com-
ments received from the Delphi panel. Panellists did not
receive feedback from the ﬁrst questionnaire. The
second questionnaire was presented in the same format
as the ﬁrst. Again, the median response and the IQR
were calculated, and the project steering group reviewed
these measures of agreement along with any additional
comments. If consensus was not reached following the
second round, the criterion was rejected.
RESULTS
Figure 1 summarises the development of the indicators.
Literature searches identiﬁed 47 potential indicators.
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Out of the total identiﬁed, 31 indicators were removed
following the application of the inclusion and exclusion
criteria along with a detailed examination of the evi-
dence by the project steering group. Remaining 16 indi-
cators were presented to the Delphi panel in the ﬁrst
round. Out of 18, 15 experts who consented to partici-
pate completed each round of the questionnaire. Three
experts did not complete either round. Consensus was
reached for nine indicators on the ﬁrst round with no
indicators being rejected; consensus was not reached on
seven indicators. From these seven indicators, two were
rejected by the project steering group on the basis of
the clinical comments of the Delphi panel. Five indica-
tors were then presented to the Delphi panel in round
two. Consensus was reached on three indicators and
none was rejected outright. Consensus was not reached
on the remaining two indicators which were then
removed by the project steering group, following review
of the comments of the Delphi panel. Table 1 sum-
marises the progression of the indicators through the
Delphi process and table 2 provides an example of some
of the comments of the Delphi panel.
DISCUSSION
We have developed a set of twelve indicators of poten-
tially inappropriate prescribing for use in children in
primary care through a modiﬁed Delphi method. These
12 indicators can be easily and quickly applied to large
prescribing or dispensing data sets in the absence of
clinical information. The indicators developed in this
study were not designed as an exhaustive list of PIPc, but
rather represent a list of commonly prescribed medica-
tions in Ireland and the UK, which may be used to
explore the prevalence of PIPc. The usefulness and val-
idity of these indicators will be investigated in future
studies using national prescription-based databases.
Comparison with existing literature
Concerns about the quality of care received by children
in the USA were highlighted in a large study in 2007,
which examined the management of common medical
conditions in primary care using 175 quality indicators
applied to the medical records of 1536 children.3 A
screening tool consisting of 104 explicit criteria for iden-
tifying the omission of prescriptions and inappropriate
prescriptions (POPI) in children has recently been
developed in France using a Delphi process.12 The POPI
tool includes propositions or indicators of inappropriate
prescribing including omissions of prescribing in the
treatment of commonly encountered paediatric health
problems, for example, management of pain and fever.
Although intended for community and hospital settings,
this tool was developed without the input of GPs and
has not yet been validated.12 A set of 35 primary care
Figure 1 Flow diagram potentially inappropriate prescribing in children (PIPc) Study.
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Table 1 Progression of indicators through the Delphi process
Indicator
Round 1
Median
IQR Outcome Revised indicator
Round 2
Median
IQR Outcome
1 Systemic antihistamines should not be prescribed to
children under 1 year.
3 (2.5–4) Revision
required
Sedating antihistamines should not be
prescribed to children under 2 years
4 (4–4) Accepted
2 Intranasal beclometasone should not be prescribed to
children under 6 years
4 (4–4) Accepted NA NA Accepted
3 Mucolytics should not be prescribed to children under
2 years
4 (3.5–5) Revision
required
Carbocysteine should not be prescribed to
children
4 (4–5) Accepted
4 An inhaled SABA should be prescribed to all children
who are prescribed two or more inhaled corticosteroids
for presumed asthma
5 (4–5) Accepted NA NA Accepted
5 An inhaled SABA should be prescribed to children
under 5 years who are also taking a leukotriene receptor
antagonist for presumed asthma.
5 (4–5) Accepted NA NA Accepted
6 An inhaled corticosteroid should be prescribed to
children aged 5–15 years who are taking a LABA
5 (4–5) Accepted NA NA Accepted
7 LABAs should not be prescribed to children under
5 years.
4 (3.5–4) Revision
required
LABA’s (either in combination or on their own)
should not be prescribed to children under
5 years. New evidence presented
4 (3.5–4) Rejected based on lack
of consensus of Delphi
panel
8 Children under 12 years who are prescribed a
pressurised metered-dose inhaler (pMDI) should also be
prescribed a spacer device at least every 12 months.
4 (4–5) Accepted NA Accepted
9 Loperamide should not be used in the treatment of
diarrhoea in children under 4 years.
4 (3.5–5) Revision
required
Loperamide should not be prescribed to
children under 4 years. New evidence
presented.
4 (4–5) Accepted
10 Domperidone should not be prescribed to children under
1 year, and for children over 1 year, it should not be
prescribed for >7 days.
<1 year
5 (3.25–5)
<7 days
4.6 (3.25–5)
Revision
required
Rejected based on comments of panel. Lack
of evidence to support.
NA Rejected
11 Domperidone should not be prescribed concomitantly
with erythromycin.
4 (4–5) Accepted NA NA Accepted
12 Codeine/dihydrocodeine medications should not be
prescribed to children under 12 years.
4 (4–5) Accepted NA NA Accepted
13 Systemic corticosteroids should not be prescribed to
children aged 5–15 years without evidence of asthma.
3 (2.5–4) Revision
required
Other than in children with asthma, systemic
corticosteroids should not be prescribed to
children aged 5–15 years.
4 (2–4) Rejected- lack of
consensus of Delphi
panel.
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quality indicators for children were also developed in
the UK in 2014 using a multistep consensus method-
ology.13 These quality indicators are based on routine
and chronic care in addition to child development and
child protection and include six prescribing indicators
of a total number of 35 indicators overall. There is an
overlap between two of these prescribing indicators and
the indicators developed in this study. ‘Children with
asthma should be prescribed a spacer’ and ‘Children
with atopic eczema should be prescribed emollients’
overlap in both studies. However, in the UK study clin-
ical and diagnostic information is required to implement
the indicators, which were designed for auditing compu-
terised primary care records, which contain codes for
clinical conditions and have yet to be validated.13 A
cross-sectional study performed in the Netherlands in
2007 examined prescribing and referral in a single
out-of-hours setting using 24 indicators developed from
national guidelines and a GP expert panel.14 These indi-
cators focused on drug choice, primarily antibiotics, in
the management of infections. In our study indicators
relating to antibiotic prescribing were excluded as clin-
ical information is required to determine the appropri-
ateness of choice of antibiotic. Nonetheless, our
indicators remain relevant to general practice as they
relate to commonly prescribed medications such as anti-
asthmatics. The largest cohort study to date of drug use
in children in Europe found that antifectives, respiratory
drugs and dermatological agents had the highest preva-
lence of use across all age groups of children.25
Strengths and limitations
This study followed a well-deﬁned process that has been
reﬁned by others in the development of similar criteria
in populations other than children, for example, The
START/STOPP criteria for detection of PIP in older
adults and the PRescribing Optimally in Middle-aged
People’s Treatment (PROMPT) criteria for detection of
PIP in middle-aged adults.9 26 The PIPc criteria were
constructed from two sources—a literature search and
the expertise of the project steering group whose
members had experience in clinical medicine in
primary care settings and in the development of quality
indicators of prescribing in other population groups. A
second strength was the broad and representative
sample of medical professionals involved in paediatric
prescribing on the Delphi panel. The panel members
were distributed across academic and clinical experience
in specialities, such as paediatrics, general practice and
pharmacy, providing a high level of (face) validity to the
process and were representative of geographically
diverse areas of Ireland and the UK. Out of 18, 15
members who agreed to participate completed both
rounds of the questionnaires. The number of rounds
and consensus method were decided in advance of ques-
tionnaire distribution with predeﬁned limits for the
acceptance, revision or rejection of indicators. Feedback
was not provided to the panellists between rounds in
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order to remove any potential bias of panellists altering
their responses to ﬁt those of the groups. The Delphi
consensus method allowed the expert panel members to
inform the development of these criteria through their
level of agreement and additional comments. Some cri-
teria were rejected by the panellists due to the difﬁculty
in determining the appropriateness of a prescribed
medication without knowledge of whether a treatment
had been initiated by a specialist. Medications which
were considered to be appropriate ‘under specialist
supervision only’ were therefore removed. Finally, to
ensure relevance to clinical general practice each indica-
tor was presented with a clear rationale that described
either a lack of clinical effectiveness or the potential
serious side effects of the relevant medication. The
rationale for the indicator was supported by the highest
level of evidence available, provided to the panel in an
easily accessible format to facilitate informed
decision-making.
The main limitation of this study relates to use of the
Delphi technique. While it is a commonly used tech-
nique, the reliability of the Delphi method for achieving
consensus has been debated in the literature. The infor-
mation gathered using a Delphi method represents the
views of chosen experts about a speciﬁc practice at a
given time and this may vary depending on the experts
involved.27 In this study, a panel size of 15 experts with
clinical and academic expertise in prescribing to chil-
dren was used to mitigate this limitation. This is thought
to be a sufﬁcient panel size when the experts have a
similar training and general understanding of the ﬁeld
of interest.28 Ideally, the level of expertise required to be
a member of the Delphi panel would be clearly deﬁned
prior to the beginning of the study.28 Nonetheless,
Table 2 Exemplar comments received from the Delphi panel on rejected indicators
Rejected following round 1
Indicator Rationale Comments
Domperidone should not be prescribed to children under
1 year, and for children over 1 year, it should not be
prescribed for more than 7 days.
Efficacy in GORD and gastroenteritis is uncertain in this age
group. Extrapyramidal side effects occur in young children.
Can be used for short-term treatment of nausea and vomiting,
maximum duration of use should not normally exceed 1 week.
‘domperidone is not evidence based for little ones’
‘would not prescribe…because of risk of extrapyramidal side
effects’
‘have used this longer term in many cases with no adverse
effects But am aware of recent questions’
‘efficacy of this drug is unproven, any drug which may mask
symptoms or disease progression should never be
prescribed for apparent gastroenteritis’
Very potent or potent topical corticosteroids should not
be prescribed to children under 1 year
Topical corticosteroids can cause adrenal suppression and
Cushing’s syndrome.
‘occasional use necessary- if a child can’t sleep won’t
grow…’
‘very rare situations this might be appropriate’
‘agree unless prescribed by a consultant’
‘if child has severe eczema they may be needed for a short
period of time’
‘possibly under dermatology guidance for rare severe
eczema’
Rejected following round 2
Indicator Rationale Comments
Other than in children with asthma, systemic
corticosteroids should not be prescribed to children aged
5–15 years.
Systemic corticosteroids can cause serious side effects
including adrenal suppression, immunosuppression and mood
disturbances. In the general paediatric population, there are
few indications for systemic corticosteroids apart from asthma
and croup. Croup commonly affects children under 5 years
‘Agree unless there is a clinical indication such as flare of
juvenile rheumatoid arthritis’
‘Exceptions being serious diseases where specialists might
prescribe. e.g, glomerulonephritis’
‘there are relatively rare indications for systemic steroids in
children- they would always be initiated by a specialist’
Long-acting β agonists (LABAs) should not be prescribed
to children under 5 years.
Use of LABAs is associated with increased risk of asthma
exacerbations, hospitalisations and asthma-related deaths in
children and adults. It is not known if combination use with
inhaled corticosteroids reduces this risk.
‘Not recommended by the British thoracic guidelines in
under 5′s’
‘Lack of fear of their pernicious side effects plus a lack of
understanding of the definition of asthma is to blame’
‘The Cochrane review summary that is attached says that
LABA does not significantly decrease exacerbations or
hospitalisations as opposed to your statement of increasing
the risk based on the SMART trial’
‘I have seen evidence of poor response to short acting
bronchodilators in those on long acting bronchodilators’
GORD, Gastro-oesophageal reflux disease; LABA, long-acting β agonists; SMART, Salmeterol Multicenter Asthma Research.
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signiﬁcant efforts were made to ensure that the Delphi
panel were heterogeneous in experience and setting to
limit this potential bias. There may be variation in
knowledge underpinning panel members’ views, but the
Delphi panel was provided with the best available evi-
dence to mitigate this effect. It may have been useful to
provide the panel with a more objective rating of the evi-
dence, for example using the GRADE system to further
aid decision-making, but this was beyond the scope of
the current study.29
Explicit prescribing criteria are limited in that they do
not address individual differences among patients or the
complexity or appropriateness of entire medication regi-
mens.30 Furthermore, they need to be regularly updated
in line with evidence, and country-speciﬁc adaptations
are necessary where countries differ in their guidelines,
standards and approved medications.
Finally, the database used in this study to determine the
prevalence of the indicators is not fully representative of
the entire population of children in Ireland. The PCRS
database contains information on prescriptions
dispensed under the means-tested GMS scheme for
which ∼39% of the population under 16 years were eli-
gible in 2014. Poorer health has been reported in socio-
economically deprived areas31 with an increased
prevalence of prescribing; therefore, the use of this data-
base would have inﬂated the prevalence of prescribing,
thus mitigating against the effects of this potential source
of bias. Unfortunately data on non-eligible patients are
not routinely collected in the Republic of Ireland.
Implications for research and practice
The examination of individual clinical information to
assess the appropriateness of prescribing can be time-
consuming and difﬁcult. These indicators can be applied
quickly and easily to large population-based data sets in the
absence of clinical information to identify PIPc unexam-
ined to date. A study to validate the indicators developed in
this study is currently underway using the PCRS database.
Changes and unwarranted variation in prescribing patterns
can be identiﬁed across time and geographical area.
Researchers in other countries outside of Ireland and the
UK could use these indicators with translation and some
modiﬁcations based on country-speciﬁc guidelines, clinical
practices and drug formularies.7 The indicators can be
used to examine the impact of changes in guidelines on
prescribing patterns on a population level, for example
asthma care. The cost of PIPc can also be examined.
The indicators may be used as a screening tool at the
level of individual clinical practices and could be used to
support detailed medication review of individual
patients. Community pharmacists, who routinely dis-
pense medications without clinical information, could
also use these indicators as a resource for clinically
checking prescriptions for children.
Identiﬁcation and quantiﬁcation of PIP in older popu-
lations has led to the development of interventions that
improve prescribing. For example, a randomised con-
trolled trial of a multifaceted intervention which
included pharmacist advice, web-based pharmaceutical
treatment algorithms and tailored patient information
leaﬂets had a positive effect on PIP in older popula-
tions.32 Integrating some of these supports into clinical
decision support systems may prove to be a practical
method of improving PIPc.
CONCLUSION
To date, research into paediatric prescribing in primary
care is lacking. This study offers a set of 12 evidence-
based explicit prescribing indicators to identify PIPc in
primary care. The application of these indicators will
enable investigation of the prevalence of PIPc and allow
examination of changes in PIPc over time.
Twitter Follow the HRB Centre for Primary Care Research at
@HRBPrimaryCare
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